%0 Case Reports
%T Durable complete response in a patient with leptomeningeal melanoma after treatment with dabrafenib, trametinib, and nivolumab.
%A Lochrin SE
%A Buonocore DJ
%A Young RJ
%A Kaley TJ
%A Postow MA
%A Wolchok JD
%A Shoushtari AN
%A Momtaz P
%A Betof Warner AS
%A Callahan MK
%J Pigment Cell Melanoma Res
%V 0
%N 0
%D 2024 Jul 3
%M 38960393
%F 4.159
%R 10.1111/pcmr.13179
%X Leptomeningeal disease (LMD) is a devastating complication of melanoma with a dismal prognosis. We present the case of a young man with stage IV BRAF V600E mutant melanoma with lung, lymph node, and brain metastases initially treated with ipilimumab and nivolumab, who subsequently developed LMD. Upon change to BRAF/MEK targeted therapy with nivolumab, a durable complete response was achieved and remains ongoing, off treatment, 7 years from diagnosis. Management of symptomatic LMD remains a critical unmet clinical challenge, with limited clinical trial data. This exceptional case is instructive, as the first published case of the use of the triplet, and the first durable response with therapy discontinuation, in melanoma LMD. The triple-drug regimen may be considered a viable option in fit patients. This case highlights the potential for long-term disease control and the critical and urgent need to develop clinical trials inclusive of patients with LMD to define the best treatment strategies.